Rigel(US:RIGL)2021-11-05 19:22TAVALISSE Sales Performance and Growth - Q3 2021 net product sales reached $16 million[17] - Bottles shipped to patients and clinics increased by 5% compared to Q3 2020[17] - A total of 1,657 bottles were shipped, including 1,710 to patients and clinics, offset by a decrease of 53 bottles in distribution channels[64] - The company maintained a strong persistency rate of 56%[9] wAIHA Opportunity - Rigel is positioned to capitalize on the warm autoimmune hemolytic anemia (wAIHA) opportunity, targeting 45,000 US adult wAIHA patients[35] - In a Phase 2 clinical trial, 44% of patients responded by Week 24, with an increase in hemoglobin levels[41] - Enrollment is complete for the wAIHA Phase 3 clinical trial[9, 44] COVID-19 Program - Rigel is exploring fostamatinib in COVID-19, with ~210 patients enrolled in the Rigel-led Phase 3 clinical trial as of November 1, 2021[9] - Government contract revenue of $1 million was related to U S DOD support for Rigel's ongoing Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients[70] Pipeline Programs - Rigel is advancing the development of its IRAK1/4 inhibitor program, with preparations for a Phase 1b/2 study in low-risk MDS underway[9] - The company is progressing both RIP1 inhibitor programs in collaboration with Lilly[9] Financial Position - Cash, cash equivalents, and short-term investment balance totaled $143.1 million as of September 30, 2021[70] - Contract revenues from collaborations reached $4.5 million, including $2.4 million from the Lilly license agreement and $1.8 million from the Daiichi milestone[69, 70]